This clinical trial studies the utilization of glutamine by the bone marrow plasma cells from patients with monoclonal gammopathy of undetermined significance (MGUS) compared to multiple myeloma (MM). Results from this study may identify metabolic differences between pre-malignant and malignant clonal plasma cells in MGUS and MM, respectively. It may also allow researchers better determine the transition from MGUS to MM for the development of potential early diagnostic purposes of preventative strategies.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT03119883.
PRIMARY OBJECTIVE:
I. Compare the glutamine anaplerosis activity in bone marrow clonal plasma cells (cPCs) between patients with MGUS and MM using an in vivo and an ex vivo approach.
SECONDARY OBJECTIVES:
I. Compare the tricarboxylic acid (TCA) isotopomer enrichment in the bone marrow plasma obtained from patients with MGUS and MM with the in vivo approach.
II. Determine the peripheral blood enrichment of 13C in the TCA cycle intermediates from patients with MGUS and MM with the in vivo approach.
OUTLINE: Patients are assigned to 1 of 2 groups.
GROUP I (EX-VIVO): After an overnight fast of 6 hours, patients undergo collection of blood samples.
GROUP II (IN VIVO): After an overnight fast of 6 hours, patients receive 13-carbon labeled glutamine or 13-carbon-labeled glucose intravenously (IV) over 90 minutes. Patients also undergo collection of blood and bone marrow aspirate samples.
After completion of study, patient are followed up for 4 weeks.
Trial PhaseNo phase specified
Trial Typebasic science
Lead OrganizationMayo Clinic in Rochester
Principal InvestigatorWilson I. Gonsalves
